LXEO: Lexeo Therapeutics, Inc. Stock

by  •  • Comments Off on LXEO: Lexeo Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 419.39
Enterprise Value ($M) 297.93
Book Value ($M) 113.53
Book Value / Share 3.45
Price / Book 3.69
NCAV ($M) 95.19
NCAV / Share 2.89
Price / NCAV 4.41

Profitability (mra)
Return on Invested Capital (ROIC) -0.53
Return on Assets (ROA) -0.68
Return on Equity (ROE) -0.92

Liquidity (mrq)
Quick Ratio 7.05
Current Ratio 7.05

Balance Sheet (mrq) ($M)
Current Assets 121.47
Assets 139.81
Liabilities 26.27
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -68.51
Net Income -66.39

Cash Flow Statement (mra) ($M)
Cash From Operations -59.50
Cash from Investing -0.17
Cash from Financing 103.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Janus Henderson Group Plc 8.70
02-14 13G D1 Capital Partners L.P. 9.40
02-14 13G Omega Fund VI, L.P. 8.10
02-14 13G Lundbeckfond Invest A/S 6.90
02-14 13G/A Citadel Advisors Llc 7.80
02-13 13G Longitude Capital Partners IV, LLC 9.60
12-15 13G/A Novo Holdings A/S 4.90 1.06
12-11 13G Eventide Asset Management, Llc 11.93

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 14,175 87,156 16.26
2024-05-02 44,705 47,116 94.88
2024-05-01 22,459 24,039 93.43
2024-04-30 29,816 30,552 97.59

(click for more detail)

Similar Companies
LNTH – Lantheus Holdings, Inc. LRMR – Larimar Therapeutics, Inc.
LUMO – Lumos Pharma, Inc. MACK – Merrimack Pharmaceuticals, Inc.
MDWD – MediWound Ltd.


Financial data and stock pages provided by
Fintel.io